Details of the Drug Reposition

General Information of This Drug (ID: DMXMAJA)

Drug Name
Fosgonimeton   DMXMAJA
Synonyms
Fosgonimeton; Fosgonimeton [INN]; Fosgonimeton [USAN]; UNII-H91OA9858J; H91OA9858J; 2093305-05-4; Fosgonimeton [USAN:INN]; ATH-1017; NDX-1017; WHO 11782; L-Isoleucinamide, O-(phosphono-kappaO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-,; ATH-1017 FREE ACID; NDX-1017 FREE ACID; CHEMBL5095419; AKOS040757261; HY-132814; CS-0204081; L-Isoleucinamide, O-(phosphono-kappaO)-N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-; dihydrogen 4-[(2S)-3-({(2S,3S)-1-[(6-amino-6-oxohexyl)amino]-3-methyl-1-oxopentan-2-yl}amino)-2-hexanamido-3-oxopropyl]phenyl phosphate
Drug Type
Small molecule
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2/3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Alzheimer disease DISF8S70 8A20 Phase 2/3 [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Parkinson disease DISQVHKL 8A00.0 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04886063) Open-Label Extension of Studies ATH-1017-AD-0201 and ATH-1017-AD-0202 in Subjects With Mild to Moderate Alzheimer's Disease. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04831281) A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies. U.S.National Institutes of Health.